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’ INTRODUCTION
Multiple Sclerosis (MScl) is a chronic progressive inﬂamma-
tory, presumably autoimmune, disease of the human central
nervous system (CNS) in which the fatty myelin sheaths that
surround the axons of the neurons of the brain and spinal cord are
damaged, leading to demyelination.1 MScl is one of the most
common neurological diseases and usually starts in early adult-
hood and progresses to serious neurological disability. It has an
enormous impact on the health care system and economy of
diﬀerent countries. Currently, MScl aﬄicts approximately one
million people worldwide, and the total cost of MScl has been
estimated at 12.5 billion h per year.2,3
The animal model of MScl, the experimental autoimmune/
allergic encephalomyelitis (EAE) model,49 has become an
important tool for understanding the human disease. EAE is a
cell-mediated experimental autoimmune disorder of the CNS
and shares its clinical expression and pathological picture with
that of MScl. For instance, the Lewis rats in which neuroin-
ﬂammation is induced by means of myelin basic protein (MBP),
as in our study here, display a typical disease curve resembling
that of the beginning of MScl relapsing-remitting type (RR-
MScl). RR-MScl is the most common type of the early stage of
MScl. EAE is therefore a useful model for the neuroinﬂammatory
aspect of MScl. Note that EAE does not mimic neurodegenera-
tion and widespread demyelination seen in MScl.10 In EAE,
demyelinationmight be present in the ventral root exit and dorsal
root entry zone of the spinal cord or even absent. Also, EAE is
monophasic, whereas MScl has a random relapsing-remitting or
chronic progressive pattern.11 EAE has led to development of the
hypothesized immunological basis of MScl pathology.12 More-
over, the EAE has been instrumental in discovering and
developing three of the six currently approved therapies for
MScl that diminish its symptoms: Copaxone, Mitoxantrone,
and Natalizumab.13,14 For instance, Mitoxantrone, a known
cancer drug, was tested in EAE and found to have positive
eﬀects, which led to its use in relapsing-remitting MScl, slowing
its progression into secondary progressive MScl.15
Unambiguous current clinical diagnosis of MScl remains
diﬃcult, particularly in its early stage, due to the complexity of
its pathology and the similarities of these pathologies to that of
other neurological diseases/inﬂammations. Diagnosis in an early
stage is important as early intervention appears beneﬁcial to slow
down the long-term progression of the disease.16 A molecular
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ABSTRACT: Multiple Sclerosis (MScl) is a neurodegenerative disease of the
CNS, associated with chronic neuroinﬂammation. Cerebrospinal ﬂuid (CSF),
being in closest interaction with CNS, was used to proﬁle neuroinﬂammation to
discover disease-speciﬁc markers. We used the commonly accepted animal model
for the neuroinﬂammatory aspect of MScl: the experimental autoimmune/allergic
encephalomyelitis (EAE). A combination of advanced 1HNMR spectroscopy and
pattern recognition methods was used to establish the metabolic proﬁle of CSF of
EAE-aﬀected rats (representing neuroinﬂammation) and of two control groups
(healthy and peripherally inﬂamed) to detect speciﬁc markers for early neuroin-
ﬂammation. We found that the CSF metabolic proﬁle for neuroinﬂammation is
distinct from healthy and peripheral inﬂammation and characterized by changes in
concentrations of metabolites such as creatine, arginine, and lysine. Using these
disease-speciﬁc markers, we were able to detect early stage neuroinﬂammation,
with high accuracy in a second independent set of animals. This conﬁrms the predictive value of these markers. These ﬁndings from
the EAE model may help to develop a molecular diagnosis for the early stage MScl in humans.
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biomarker derived for neuroinﬂammation in the animal model
EAE may form a ﬁrst step toward such an early diagnosis.
Themain objective of this study is to ﬁnd in the cerebrospinal
ﬂuid (CSF) of EAE induced Lewis rats metabolic markers of
neuroinﬂammation and to diﬀerentiate neuroinﬂammation
from peripheral inﬂammation. For this a controlled animal
study was setup, with a healthy control group, a group injected
with inﬂammatory “booster” (Complete Freund Adjuvant
emulsion, CFA) to induce peripheral inﬂammation and a group
injected with CFA and in addition MBP to induce neuroin-
ﬂammation. Disease progression was monitored, and CSF
samples were collected at two diﬀerent time points. To analyze
the metabolic proﬁle of the CSF, we used an untargeted and
unbiased biomarker discovery approach in which high-ﬁeld 1D
1H NMR is combined with pattern recognition methods. To
our knowledge, this is the ﬁrst study applying 1H NMR to
analyze rat CSF in the EAE model. A fact that very few rat CSF
metabolite studies have been done by NMR is likely due to the
limited amount of CSF in rodents. This is not a standard
procedure to use such little sample volume in NMR. High
quality data could be obtained using only 10 μL of CSF, thanks
to the use of advanced NMR including high-ﬁeld and cryo-
probe technology.
We found that the CSF metabolic proﬁle for neuroinﬂamma-
tion is distinct from that of healthy and peripheral inﬂammation.
The metabolites, identiﬁed as speciﬁc for neuroinﬂammation,
were investigated in a second independent set of animals for the
prediction of the early stage of neuroinﬂammation. The valida-
tion of the ﬁndings with an external experiment is often
acclaimed but rarely practiced in a single study. These disease-
speciﬁc markers, detected in the animal model, may lead to a
better understanding of the metabolism underlying neuroinﬂam-
mation and help to develop a molecular diagnosis for the early
stage of MScl in humans.
’MATERIALS AND METHODS
Experimental Design of EAE Models
The EAE is one of the most intensively examined and best
characterized animal models of autoimmune disease.9 EAE
shares similarities with MScl. Although the EAE model does
not mimic all aspects of MScl, this rodent disease model is an
excellent experimental system for understanding aspects of the
MScl disease.
The ﬁrst set of male Lewis rats (Harlan Laboratories B.V., The
Netherlands) was inoculated on Day 0 as previously described.17
Figure 1. (a) EAE disease progression. (b) Average neurological score screened for group “N14”. The vertical bars indicate standard error of the mean.
(c) 1H-800 MHz NMR spectrum of rat CSF. Vertical lines indicate the bins. (d) PCA score plot of the 1H NMR spectra of rat CSF.
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Brieﬂy, a 100 μL saline based emulsion containing 50 μL of
Complete Freund Adjuvant H37 RA (CFA, Difco Laboratories,
Detroit, MI), 500 μL of Mycobacterium tuberculosis type H37RA
(Difco), and 20 μg guinea pig myelin basic protein (MBP) was
injected subcutaneously in the pad of the left hind paw of
isoﬂurane anaesthetized animals. CFA was injected for boosting
of the immune system, while MBP was injected for induction of
neuroinﬂammation. Next to these MBP challenged rats, referred
to as the EAE group (or neuroinﬂamed group), two control
groups were included: a group of animals receiving the same
emulsion without MBP (CFA group = peripheral inﬂammation)
and a healthy group undergoing anesthesia only (healthy
control). Each group consisted of 30 animals. In each group,
half of the animals was sacriﬁced to collect CSF on Day 10 (Day
of onset in EAE group) and the other half on Day 14 (peak of
disease in EAE group). The typical progression of disease is
shown in Figure 1, while the design of the ﬁrst EAE experiment is
summarized in Table 1.
Animals were kept under normal housing conditions with
water and food and libitum, weighing between 175 and 225 g at
the start of the experiment. Animals were group housed per 3 and
cages were randomized across treatments and disease duration.
A second set of male Lewis rats was used to perform another
EAE experiment, one year after the ﬁrst one. The animals were
inoculated with CFA and/or MBP as described above. The
experimental design, the amount of animals (i.e., 15 animals
per group) and settings of this model were similar to the ﬁrst one.
The experimental design and the number of animals per group
are summarized in Table 1 in the Supporting Information.
Data Acquisition and Analysis
Neurological Scores. Disease symptoms and weights of all
animals from both EAE models were recorded daily. The
following scores for motor dysfunctions were used: 0, healthy
animal with normal curling reflex at the tail; 1, paralysis of the tip
of the tail; 2, loss of muscle tone at the base of the tail; 3, low
posture of hind limbs; 4, instability at hips; 5, partial hind limb
paralysis; 6, complete hind limb paralysis; 7, paralysis include
midriff; 8, quadriplegia; 9, moribund; 10, death due to EAE
(Supporting Information). All experimental procedures were
approved by Abbott’s Institutional Animal Care and Use
Committee.
CSF Sampling, Sample Preparation and Data Acquisi-
tion.OnDay 10 and 14, animals were euthanized with CO2/O2.
Terminal CSF samples were obtained by direct insertion of an
insulin syringe needle (Myjector, 29G 1/200) via the arachnoid
membrane into the Cisterna Magna. For this purpose, a skin
incision was made followed by a horizontal incision in the
musculus trapezius pars descendens to reveal the arachnoid
membrane. A maximum volume of 60 μL of CSF was collected
per animal. Each sample was centrifuged within 20 min after
sampling, for 10 min at 2000 g at 4 C. After centrifugation, the
supernatants were stored at80 C for further analysis. Previous
experiments have shown that collecting up to 60 μL using this
technique under these conditions provides hemoglobin-free CSF
samples as measured by ESI-Orbitrap (unpublished data). As an
additional check, fresh samples, supernatant, and pellet size were
visually scored for hemolysis and samples were discarded if
positive.
From the set of 90 samples from the ﬁrst EAE experiment
(Table 1), 4 were contaminated with blood therefore they were
excluded from the measurements. A set of 86 CSF samples were
prepared and measured as described below.
10 μL of rat CSF were thawed at room temperature and
240 μLD2O (99.96 at.%D) were added to the bioﬂuid in order to
obtain suﬃcient amount of sample for the NMR measurement.
TSP-d4 (Sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4) (99
at.%D) was used as internal standard for chemical shift reference
(δ 0.00 ppm). For the latter, 25 μL of 8.8 mM TSP-d4 stock
solution in D2O was added to 250 μL of rat CSF to a ﬁnal
concentration of 0.8 mM TSP. The TSP-d4 stock was prepared
by weighing in dry TSP-d4. The pH of the CSF was adjusted to
around 7 (7.07.1) by adding phosphate buﬀer (9.7 μL 1M, to a
ﬁnal concentration of 35 mM). The ﬁnal CSF NMR sample
(284.7 μL) was then transferred to a SHIGEMI microcell tube
for measurements.
The 1D 1HNMR spectra of rat CSF samples were acquired on
an 800MHz Inova (Varian) system equipped with a 5 mm triple-
resonance, Z-gradient HCN cold-probe. Suppression of water
was achieved by using WATERGATE (delay: 85 μs).18 For each
1D 1H NMR spectrum, 512 scans were accumulated with a
spectral width of 9000 Hz resulting in a total of 18K points. The
acquisition time for each scan was 2s. Between scans, a 8s
relaxation delay was employed. Prior to spectral analysis, all
acquired Free Induction Decays (FIDs) were zero-ﬁlled to 32K
data points, multiplied with a 0.3 Hz line broadening function,
Fourier transformed, manually phased and the TSP internal
reference peak was set to 0 ppm by using ACD/SpecManager
software version 11.0.19 All 86 rat CSF spectra were acquired and
preprocessed as described above. However, due to high line
broadening of the internal standard (TSP), four spectra were not
included in spectral analysis. In total, 82 spectra were subsequently
transferred to Matlab, version 7.6 (R2008b) (Mathworks, Natick,
MA), for further analysis.
The preparation and data acquisition of CSF samples from the
second EAE experiment are described in the Supporting
Information.
Preprocessing of NMR Spectra. The NMR spectral data
were preprocessed, which typically involves baseline correction,
alignment, binning, normalization and scaling. Baseline correc-
tion of NMR spectra was performed by applying Asymmetric
Least Squares method.20 Fluctuation in experimental conditions
like sample temperature, pH, ionic strength can lead to chemical
shift variations, therefore NMR spectra were aligned by using
improved parametric time warping (I-PTW).21 A further pro-
blem is the high dimensionality of the data (ca. 10 000 variables).
It is common to apply binning to this kind of data, which reduces
the number of variables. To perform proper spectral bucketing
we used adaptive intelligent binning.22 The chemical shift range
δ 0.754.15was used for the binningprocedure because it contained
relevant information.Next, spectral resonances corresponding to one
Table 1. Experimental Design of EAE Modela
treatment day 0 group description day 10 day 14
Anesthesia only Healthy C10 C14
n = 15 n = 15
CFA Peripheral inﬂammation P10 P14
n = 15 n = 15
CFA+MBP Neuroinﬂammation + peripheral
inﬂammation
N10b N14c
n = 15 n = 15
a n indicates number of rats (samples) for each group. bOne sample was
discarded due to blood contamination. cThree samples were discarded
due to blood contamination.
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metabolite were summed and regrouped in one bin. This
procedure was applied to the resonances where no overlapping
was present and it led to 153 bins in total. To make spectra
comparable between different samples, the final step of prepro-
cessing consisted of integral normalization and supervised vast
scaling applied to the binned data.23
Metabolites Identification and Quantification.Metabo-
lite identification was carried out by using the 800MHz library of
metabolite NMR spectra from the Chenomx NMR Suite 5.1
(pH 68). The library of metabolite spectra is obtained based on
a database of pure compound spectra acquired using a particular
pulse sequence and acquisition parameters, the tn-noesy-pre-
saturation pulse sequence with 4s acquisition time and 1s of
recycle delay.24 The Chenomx NMR Suite software fits the
spectral signatures (singlets, doublets, triplets etc), that is, the
peak shapes, of a compound from an internal database of
reference spectra to the experimental NMR spectrum.
For quantiﬁcation, that is determination of the concentrations
of individual metabolites, Chenomx NMR Suite 5.1 uses the
concentration of the known reference signal as calibration (in this
case TSP-d4). Note that the Chenomx approach is that peak
shapes are ﬁtted to the experimental ones. In contrast, peak
integration, which is often employed for quantiﬁcation, is very
sensitive to baseline distortions and even slightly overlapping
resonances cannot reliably be integrated. Peak-shape ﬁtting, like
employed in Chenomx, is instead not much aﬀected by baseline
distortions. Moreover, even when some of the resonances and/or
part of a resonance signature (triplet etc.) of a compound overlap
with that of another compound, the peak shape can still be ﬁtted
with reasonable accuracy and the concentration of the compound
reliably determined.
Data Analysis Strategy. Explorative analysis, by means of
Principal Component Analysis (PCA),25 was used first to extract
and display the systematic variation in the data.
The strategy for multivariate supervised analysis, using Dis-
criminant Analysis by Projection on Latent Structures (PLS-
DA)26 was designed in accordance with the experimental design
summarized in Table 1. The data contain three main groups
(healthy control “C10” and “C1400, peripheral inﬂammation
“P10” and “P14” and mixture of neuroinﬂammation and periph-
eral inﬂammation “N10” and “N14”) in two time points (Day 10
and Day 14). The two time points (Day 10 and Day 14) were
analyzed separately, and we always diﬀerentiated between two
groups. We have used PLS-DA, since it gives more interpretable
results and it enabled us to observe the inﬂuence of single eﬀects
(i.e., peripheral inﬂammation, neuroinﬂammation or disease-
progression) on the CSF metabolic proﬁle.
To corroborate the results we used another supervised method,
ANalysis Of VAriance-Principal Component Analysis (ANOVA-
PCA). The analysis was performed on each time point separately as
well as on the two time points combined. Variables (metabolites)
diﬀerentially proﬁled across groups of interest were selected based
on regression coeﬃcients in PLS-DA and on ANOVA-PCA,
Hotelling T2 statistic with p-value inferior than 0.05.27
Model Construction and Validation. PLS-DA is a varia-
tion of PLS.28 PLS-DA uses the group information to maximize
the separation between groups of observations. It is currently
widely used in metabolomics because of its ability to cope with
high correlations between variables. In PLS-DA a linear model is
constructed according to eq 1:
y ¼ Xb þ r ð1Þ
where, X is a data set matrix, y is a vector of group memberships,
b is a vector of regression coefficient, and r is a vector of model
residuals. The regression coefficients reflect the relative impor-
tance of the variables in the PLS-DA model. We divided the data
into a training and a test set using the Duplex algorithm29 in such
a way that the number of samples in the training set was equal for
every considered group. The amount of samples in the test set
was equal to at least 25% of the total number of samples but not
more than 30%. To prevent model overfitting we applied the
cross model validation (CMV) procedure, introduced by An-
derssen et al and Gidskehaug et al.30,31 in which double cross
validation procedures are included for model optimization, the
variable selection based on jack-knifing and final model perfor-
mance assessment. All MATLAB routines for performing vari-
able selection can be found in this reference.31
Finally, all PLS-DA models were validated with the indepen-
dent test set. For every considered model the speciﬁcity and
sensitivity of the test set were calculated. The ﬁnal PLS-DA
model was applied to the whole data set if the accuracy of the
independent test set was satisfactory (i.e., above 90% of correct
classiﬁcation).
In order to predict the class labels (Y^) of validation set the
scaled spectra (Xnew) have to be multiplied by regression
coeﬃcient (b) obtained from PLS-DA model (i.e., Y^ = Xnewb).
Please keep in mind that scaling performed on validation set
applied all necessary parameters (i.e., mean and standard
deviation) from training set.
ANOVA-PCA. Previously we showed that this approach
allows identifying the relevant variables to distinguish groups.27
In this study the main factors are the metabolites effect (M) and
the treatments effect (T) (groups) plus a random dimension
linked to the individual variations. The ANOVA model is given
in eq 2:
Xijk ¼ μ þ þMi þ Tj þ MTij þ eijk ð2Þ
where μ is a general mean, e is the error term and MTij indicates
the interactions between main effects. The interaction between
metabolites and treatments, that is, groups (MTij), is of highest
interest because it reflects the influence of the different treat-
ments on the intensity of metabolites when all others effects are
averaged out. Therefore PCA is performed on the matrix of
interaction effects to identify metabolites that contribute to this
interaction. If the treatment (j) is relevant for the metabolite (i),
the interaction MTij is significantly different from zero.
Heat Map and Correlation Network Map. To represent
the relevant metabolites concentrations in groups “C14”, “P10”
and “N14” we generated a heat map from NMR metabolomics
data. The heat map is a graphical representation of NMR
data in two-dimensional map, where the metabolites concentra-
tions are illustrated as colors. Every concentration value was
standardized according to the reference group (healthy group
“C14”), i.e. by subtracting mean and dividing by the standard
deviation of healthy controls. In that way the metabolites
concentrations are expressed in values of standard deviation
from the control group.
The concentration of a certain metabolite does not ﬂuctuate
independently, but may be correlated and change with the others
metabolites. To examine the level of observed changes among
metabolites we calculated the Spearman’s correlation between
relative metabolites concentrations in groups “C14” and “N14”,
as well in groups “P10” and “N14”. Spearman correlation
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calculates the correlation of the ranks for metabolites concentra-






nðn2  1Þ ð3Þ
where, Cr is a Spearman’s correlation, di is a diﬀerence between
ranks of each sample on the twometabolites, and n is the number
of samples.
Extreme variations in concentration values have less inﬂuence
on the Spearman correlation than on the Pearson’s correlation.
The calculated correlations are then transferred to Graphviz 1.01
for network map visualization (http://www.graphviz.org). In the
network map two metabolites are connected with a link if their
correlation coeﬃcient is relevant, that is, exceeds a given thresh-
old. The correlation between metabolites concentrations was
signiﬁcant if its value was superior than 0.7 and p-value was
inferior than 0.05.
’RESULTS
Overview of the Available Data
Eighty-six NMR spectra were measured, while 82 spectra were
included in further analysis. An example of a 1H NMR spectrum
of rat CSF is shown in Figure 1c in the chemical shift region
between 0.8 and 2.7 ppm. This region contains several signals
from carboxylic acids and amino acids protons. Some of the
metabolites are named in Figure 1c. For the analysis, the NMR
spectra were divided into 153 bins, which contain resonances of
33 identiﬁed metabolites and some unidentiﬁed signals. The
identiﬁed metabolites are listed in the Supporting Information.
The information concerning the second EAEmodel can be found
in the Supporting Information.
The average neurological scores and standard deviations for
group “N14” are shown in Figure 1b, the information of each
individual animal is listed in the Supporting Information. As can
be observed, the animals showed motor dysfunction at day 11.
The average day of onset was 11.56 ((0.2). This means that on
average, animals were disabled for a period of 2.4 days ((0.2) at
the sampling day. In group “N14” only one animal showed
disease duration shorter than 2 days (onset on day 13). The
maximum score reached was on average 4.5 ((0.2). Six animals
showed a maximum score above this average. The average peak
day (as deﬁned by the ﬁrst day of maximum score per individual
animal) was 13.3 ((0.2). An idea would be to use the neurolog-
ical scores for regression purpose for groups “N10” and “N14”.
However all animals in group “N10” had neurological scores
equal zero, while animals in group “N14” quite spread values
from 0 until 6. This would cause an artiﬁcial compactness of
samples from group “N10”, while group “N14” very spread. This
would lead to biased PLS results. Therefore, the neurological
scores were not used.
Explorative Analysis by PCA
Before performing pattern recognition, the spectra of 82 rat
CSF samples were checked for outliers. In total 3 spectra were
detected as outliers and were removed from the ﬁnal analysis.
Figure 1d shows the PCA score plot of the total data set (79 vast
scaled spectra). This plot shows that the samples belonging to
group “N14” are clearly separated from the others samples along
PC2. It also reveals that a large source of variance in the data does
not correspond to the available groups. No clear grouping is
present since most of the groups overlap. With PCA only, we are
not able to distinguish all analyzed groups. Therefore, we needed
to use more dedicated methods.
Supervised Multivariate Analysis by PLS-DA and ANOVA-PCA
PLS-DA of 1H NMR CSF Data. PLS-DA models of the 1H
NMR spectra were performed to extract information on the
metabolic effects of the different group treatments as presented
in Table 1. In Table 2 in the Supporting Information, the
specificity, sensitivity, the correct classification rate for the test
set and the total number of variables in the PLS-DA models are
presented.Metabolites that contributed significantly to the group
separation are listed in Table 3 in the Supporting Information.
The results of these PLS-DA models urged us to revise the
assumed effects for some groups of Table 1. The summary of the
particular effects investigated by the different PLS-DA models is
presented in Table 4 in the Supporting Information. As the first
part of supervised analysis the comparison between “C10” and
“C14” has been performed in order to find the metabolites that
represent metabolic evolution over days. Later, this information
was used to check if any of the discriminating metabolites are
related to metabolic variation over time. Following, a detailed
analysis of the results of the different models is given.
The score plots of ﬁnal PLS-DA models are presented in
Figures 2ae. Note that score plots are used only for illustration
purpose and do not determine the classiﬁcation of PLS-DA model.
Effect of Neuroinflammation and Peripheral Inflamma-
tion. The PLS-DA model for groups “C10” versus “N10” allows
one to study the combined effect of neuroinflammation and
peripheral inflammation. This model has a high prediction ability
of 100% for the independent test set. The area under the curve
(93.4%) indicates that group “C10” and group “N10” are well
separated and the PLS-DA has a high model performance. The
CSF metabolic profile of the EAE-affected group can thus
without a doubt be differentiated from the metabolic profile of
the healthy group.
Effect of Neuroinflammation.The PLS-DAmodel for groups
“P10” versus “N10” allows one to discriminate the effects of
peripheral inflammation and neuroinflammation on the CSF
metabolic profile. This model shows poor prediction (accuracy
for the independent test set is 62.5%), and the sensitivity for
group “N10” is very low (predicted as belonging to group “P10”).
The score plot (Figure 2b) illustrates two subgroups in group
“N10”, one overlapping with group “P10” and a second cluster
further away. This result suggests that animals in group “N10” are
heterogeneous regarding to the disease response. Probably,
within group “N10” some animals did not show any neuroin-
flammation yet; indeed at Day 10, no neurological deficits have
been observed in this particular experiment. Therefore, for some
animals the peripheral inflammation is still the dominant effect
since the neuroinflammation has not developed yet. A hierarchical
clustering was performed on group “N10” to confirm the hetero-
geneity of the group (data not shown). Three samples were
identified as outliers for group “N10”. This suggests that the
response of the animals to the disease in the EAE model was not
uniform and some animals’ response is shifted along time. The
neurological scores recorded for group “N10” on average were
equal to 0. This means that by examination of the rat’s motor
system no external neurological or pathological physical signs were
observed. The heterogeneity of group “N14” was further investi-
gatedwith ROCcurve analysis. The area under curve (60%) shows
that group “P10” and group “N10” are not well separated.
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The PLS-DAmodel for groups “N10” versus “N14” allows one
to study the progression of disease. The classiﬁcation model has
perfect accuracy (overall classiﬁcation of 100% for independent
test set).
Investigation of the second time point (Day 14) by PLS-DA
allows one to identify the metabolites diﬀerently proﬁled during
the peak of disease. The PLS-DA model of “C14” versus “N14”
has perfect prediction ability (overall classiﬁcation is 100% for
independent test set).
Effect of Peripheral Inflammation during the Peak of the
Disease. The overall correct classification rate for independent
test set of this model is only 65%. The area under the ROC curve
Figure 2. PLS-DA score plots derived from 1HNMR spectra of rat CSF belonging to: (a) groups “C10” and “N10”. The amount of Y explained variance
for two latent variables was equal to 87.9%; (b) groups “P10” and “N10”. The amount of explained variance in Y for two latent variables was equal 58.3%;
(c) groups “N10” and “N14”. The amount of explained variance in Y for one latent variable was equal to 89.6%; (d) groups “C14” and “N14”. The
amount of explained variance in Y for one latent variable was equal to 95.2%; (e) groups “P10” and “N14”. The amount of explained variance in Y for one
latent variable was equal to 97.1%; (f) The projection of the independent samples from the second EAEmodel (group “P102” and group “N102”) on
the PLS-DA score plot derived from group “P10” versus “N14” of the ﬁrst EAE model.
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is 59%. These results suggest that the metabolic profiles of group
“C14” and group “P14” are quite similar. On the basis of these
data, we can make the statement that at Day 14 the effect of an
immunopotentiator, that is, CFA, was not measurable based on
the metabolite profile. Our interpretation of these results is that
peripheral inflammation has vanished byDay 14 and group “P14”
is actually healthy. This interpretation is coherent with the
absence of external symptoms (i.e., fever and swelling pad).
Since group “P14” is not inflamed anymore, the PLS-DA models
of group “P14” vs “N14” and “N14” vs (“C14&P14”) give similar
results as the PLS-DAmodel of the healthy group “C14” vs group
“N14”. In both situations, the overall correct classification for
independent test set is 100%. The PLS-DA model of “P10” vs
“P14” is described in the Supporting Information.
P10 vs N14: Peripheral Inflammation Effect versus Neu-
roinflammation Effect.On the basis of the experimental design,
the effect in group “N14” is a combination of peripheral inflamma-
tion (CFA effect) and neuroinflammation (MBP effect). How-
ever, considering the conclusion that at Day 14 the peripheral
inflammation has vanished, group “N14” should show only
neuroinflammation. Because group “N10” was heterogeneous
in disease onset, we used groups “P10” and “N14” to distin-
guish peripheral inflammation from neuroinflammation. We
performed this comparison, knowing that groups “P10” and
“N14” represent different conditions, that is, Day 10 for group
“P10” and Day 14 for group “N14”. This comparison should
yield the metabolites influenced by peripheral inflammation
or neuroinflammation.
The “P10” vs”N14” PLS-DA model should carry the informa-
tion about the metabolites diﬀerentially proﬁled in peripherally
inﬂamed and neuroinﬂamed subjects. The PLS-DAmodel shows
perfect prediction ability with an overall correct classiﬁcation of
100% for independent test set. On the basis of our results, these
two groups indeed have diﬀerent metabolic proﬁles.
ANOVA-PCA of 1H NMR CSF Data. To confirm the results
from the PLS-DA models, we used ANOVA-PCA as a corro-
borative technique to identify metabolites that vary significantly
between groups. The factors modeled in this study are the factor
treatment (CFA, CFA+MBP or no treatment) and the different
metabolites (the Metabolite factor). The resulting biplots of the
ANOVA-PCA are displayed in Figure 2ad, while the group
specific metabolites are summarized in Table 5 in the Supporting
Information. In the next section, an overview of the results
derived from ANOVA-PCA is discussed.
Except for a few metabolites, the same set of metabolites for
peripheral as well as neuroinﬂammation was selected by ANO-
VA-PCA. ANOVA-PCA showed that the metabolic proﬁles of
healthy group, peripheral inﬂamed and neuroinﬂamed animals
can be distinguished. Moreover it showed that groups “C14” and
“P14” have similar metabolic proﬁles.
The most discriminating metabolites and their absolute con-
centrations are presented in Table 2; their short biological
interpretation is further discussed in the section Discussion
and Conclusion.
As a ﬁnal step, to make the PLS-DA model more robust and
generic (i.e., machine independent), PLS-DA model was con-
structed for the absolute concentration of the metabolites. This
is, however, a time-consuming step, and therefore, we performed
it only for the “P10” and “N14” groups. The PLS-DA model for
group “P10” versus group “N14” shows perfect prediction ability
with an accuracy of 100% on the independent test set. The score
plot of this model is shown in the Supporting Information
(Figure 3). This model is further validated with an independent
set of animals, derived from a second EAE experiment.
Heat Map and Correlation Network Map
To represent the individual diﬀerences in metabolites con-
centrations of healthy controls (“C14”), peripherally inﬂamed
(“P10”) and neuroinﬂamed (“N14”) animals, a heat map of the
metabolomics data was constructed (Figure 3a). The metabolite
concentrations were standardized with respect to the healthy
group “C14”. The metabolites included in the heat map corre-
spond to the signiﬁcant ones shown in Table 2. The heat map
shows that the metabolite concentrations, characteristic for
neuroinﬂammation, change signiﬁcantly in group “N14”. For
instance, arginine concentration is elevated in group “N14” in
comparison to healthy and peripherally inﬂamed controls. On
the contrary, alanine is reduced. The intraindividual variations
are still observable.
Table 2. Average Absolute Concentration (Cμ) and StandardDeviation (σ) ofMetabolites Important for Peripheral Inﬂammation
or Neuroinﬂammation Selected based on PLS-DA and ANOVA-PCA
groups
healthy P10 N10 N14
metabolites Cμ [μM] σ [μM] Cμ [μM] σ [μM] Cμ [μM] σ [μM] Cμ [μM] σ [μM]
NAAa 13.5 2.5 14.8 1.7 16.5 2.3 21.0 3.6
arginine 39.0 10.5 37.5 8.4 46.2 11.8 62.3 17.8
lysine 72.5 9.6 68.5 11.6 89.0 15.0 135.6 29.5
choline 5.6 1.4 5.9 1.2 8.0 1.1 10.6 1.8
malonate 120.4 17.2 126.6 17.2 122.2 33.2 40.5 10.9
alanine 51.9 5.1 55.5 7.3 51.8 8.8 34.3 4.6
citrate 200.2 21.8 143.0 21.2 145.9 37.5 105.4 23.5
creatine 70.6 9.3 69.1 11.2 80.1 9.1 91.3 8.7
glutamine 606.4 93.4 531.9 96.4 544.7 71.6 654.3 127.2
lactate 2660 551.9 2757.3 387.2 3723.0 671.8 2869.3 282.0
3-hydroxya 494.4 17.2 430.7 25.8 439.9 33.5 510.8 15.4
a 3-Hydroxy stands for 3hydroxyisovalerate; NAA stands for N-acetylaspartate.
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To assess the correlation between metabolites, we calculated
Spearman’s correlation between relative metabolites concentra-
tions in groups “C14” and “N14”, as well as in groups “P10” and
“N14”. Those correlations are visualized as a network map
(Figure 3bc) to provide an overview of similarities between
diﬀerent metabolites in the considered groups. In Figure 3b, a
correlation network map between metabolites in healthy group
“C14” and neuroinﬂamed group “N14” is presented. There are
just a few shared correlations (indicated with a dashed line), that
is, signiﬁcant correlations seen in both groups. These correlations
are thus not inﬂuenced by neuroinﬂammation. Figure 3c shows
the correlation network map betweenmetabolites in peripherally
inﬂamed group “P10” and neuroinﬂamed group “N14”. There
are only a few correlations present in group “P10” (solid, black
line), and shared correlations between groups “P10” and “N14”
are absent. What is particularly noteworthy is the fact that many
correlations, present in the healthy control, vanished due to
neuroinﬂammation, but also some new correlations appeared.
Prediction of Neuroinflammation in an Independent Set of
Animals
To conﬁrm the validity of the discovered disease speciﬁc
markers for neuroinﬂammation, we used an independent set of
samples coming from another EAE experiment, in which we want
to predict neuroinﬂammation in an early stage. The absolute
concentration of our markers was determined for the group with
peripheral inﬂammation at Day 10 (here called group “P102”)
and the group with peripheral and early neuroinﬂammation at
Day 10 (here called group “N102”). All peripherally inﬂamed
animals (group “P102”) are correctly classiﬁed. Animals with
peripheral inﬂammation and early neuroinﬂammation (group
“N102”) are also correctly classiﬁed, except for one animal.
The overall correct classiﬁcation for the independent set of
samples is 95.8%, with speciﬁcity for group “P102” and group
“N102” equal to 100% and 91%, respectively. The projection of
these independent samples on the PLS-DA score plot derived
from group “P10” versus “N10” is shown in Figure 2f. It is
important to note that the misclassiﬁed sample is located close to
the borderline between the two groups. This result suggests that
proposed markers have a similar behavior in the second study.
’DISCUSSION AND CONCLUSION
Supervised analysis of CSF 1H NMR data revealed signiﬁcant
changes in biochemical composition of the CSFmetabolic proﬁle
among the analyzed groups. PLS-DA and ANOVA-PCA have
been used to model the metabolic proﬁles from rat CSF. The
small diﬀerences between PLS-DA and ANOVA-PCA results
Figure 3. (a) Heat map of selected metabolites for groups “C140 0, “P10” and “N14”. Each row represents a metabolite, and each column corresponds to
an animal from healthy group “C14” or peripherally inﬂamed group “P100 0, or neuroinﬂamed group “N14”. The relative metabolite concentrations were
standardized with respect to healthy group. Red and blue colors represent elevation or reduction of a given metabolite concentration, respectively. NAA
stands for N-acetylaspartate, while σ indicates the standard deviation of the healthy control. Correlation network map between metabolites identiﬁed
with high certainty (b) in healthy group “C14” and neuroinﬂamed group “N14” and (c) in peripherally inﬂamed group “P10” and neuroinﬂamed group
“N14”. A solid black line indicates a signiﬁcant correlation (i.e., correlation > 0.7 and p < 0.05) occurring in the ﬁrst group (healthy group “C14” or
peripherally inﬂamed group “P10”). A dotted line signiﬁes the signiﬁcant correlation unique for neuroinﬂamed group “N14”. A dashed line represents a
signiﬁcant correlation seen in each group. The red and blue boxes represent elevated or reduced metabolite concentrations in neuroinﬂamed group
“N14”, respectively. NAA stands for N-acetyaspartate.
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may arise from the principles of the two methods. PLS-DA aims
to select a subset of metabolites that gives the highest separations
between groups. This may imply that not all discriminatory
metabolites are selected. In the case of ANOVA-PCA, the
amount of selected variables mostly depend on R level Hotelling
T2. In addition, the two diﬀerent scaling approaches applied
before PLS-DA and ANOVA-PCA may have an inﬂuence on the
selection of metabolites.
Interpretation of PLS-DAmodels and ANOVA-PCA yielded a
set of relevant metabolites, which are shown in Table 2. In this
section we further discuss their biological interpretation
Metabolites Related to Neuroinflammation: Choline, N-Acet-
ylaspartate, Creatine, Lysine, Arginine, Alanine andMalonate
The concentration of choline was elevated in groups “N10”
and “N14”. However, the choline concentration stayed invariable
between two control groups “C10” and “P10”. In a previous
study, where MScl patients and EAE model in marmoset were
studied by 1HNMR spectroscopy, higher choline concentrations
have been reported as amarker for demyelination in urine.32 This
metabolite is required for synthesis of neurotransmitter acetyl-
choline, and phosphatidylcholine. The increase in choline con-
centration could be due to demyelination and/or cell membrane
breakdown.
Another metabolite found as being highly correlated with
EAE-aﬀected groups “N10” and “N14” and that enabled us to
diﬀerentiate these groups from the others was N-acetylaspartate
(NAA). This compound is known as a marker of neuronal
damage. Its concentration was elevated in the “N14” group. In
addition, this metabolite distinguished neuroinﬂammation from
peripheral inﬂammation in the PLS-DA model. NAA is a free
amino acid present in neuronal cell, and it has been culpably
involved in many processes of the nervous system, for instance, it
may be involved in the myelin production, regulation of neuronal
protein synthesis, or the metabolism of several neurotransmitters
such as aspartate or N-acetyl-aspartyl-glutamate.
Two other metabolites, creatine and malonate, were found to
vary between the two EAE-eﬀected groups. Creatine level was
found to be up-regulated in group “N14”. Creatine is considered
as one of the principal brain metabolite. Its changes in concen-
tration are seen in many other neuro-degenerative disorders and
are caused by gliosis33 or scarring of neuron (demyelination). An
elevated level of creatine in patients with MScl was found in a
previous study and has been associated as marker of gliosis.3436
Up-regulated creatine level could be due to a change in the
cellular composition, either increased inﬂammatory cells or glial
cells. The malonate level was reduced in neuroinﬂamed group
“N14”. Another metabolite found to be reduced in neuroin-
ﬂamed group “N14” is alanine. Reduced level of alanine in
patients with MScl in comparison to patients with cerebrovas-
cular disease was found in a previous study, where Sinclair et al.
used NMR spectroscopy to evaluate the ability of metabolomics
analysis to diﬀerentiate neurological disease.37 Alanine is used as
a source for pyruvate for energy metabolism or to synthesis of
macromolecules within neural and immune cells.38 Reduction of
alanine concentration may be connected to energy metabolism,
since it might be used by invading cells.
Lysine and arginine were found to have a high correlation with
EAE-aﬀected groups “N10” and “N14”. Lysine and arginine
levels were up-regulated in group “N14” compared to “N10”
and in “N10” compared to “P10”. This indicates their relation to
neuroinﬂammation. Lysine and arginine aremetabolites that may
diﬀerentiate peripheral inﬂammation from neuroinﬂammation.
Arginine is used to synthesize nitric oxide (NO). Elevated levels
of NO oxidation products in the CNS have been shown in
bacterial meningitis in cerebral lupus erythematosus. Recently it
was demonstrated that increased levels of NO oxidation plays a
part in the generation of MScl symptoms.39 Inhibition of NO
synthesis may suppress40 or emphasis EAE.41 However, the
precise role of NO in EAE and MScl still remains elusive and
unclear. Qureshi and cowworkers have studied a role of neuro-
transmitters amino asids in CSF of MScl patients.42 They have
reported increased level of lysine in CSF in MScl patiens.
Metabolites Related to Peripheral Inflammation: Citrate,
Glutamine, Lactate and 3-Hydroxyisovalerate
Citrate is a key metabolite to diﬀerentiate the healthy group
“C10” from the peripherally inﬂamed group “P10” but also the
peripherally inﬂamed group from the EAE aﬀected group “N14”.
Reduced citrate is in line with a previous study of Sinclair and co-
workers.37 The diﬀerence in citrate level is larger between the
peripherally inﬂamed and neuroinﬂamed group than between the
healthy control and the peripherally inﬂamed group. The citrate
level may indicate the degree of inﬂammation. Citrate is released
to a larger extent from astrocytes than from neurons. This
metabolite is an intermediate in tricarboxylic acid cycle (TCA).
In the study of Smith and co-workers,43 the metabolic activity of
proteins from myelin and nonmyelin fractions of spinal cords of
Lewis rats with EAE was investigated using [1-14C]leucine as a
protein precursor. In this study, they showed that the decreased
activity of the TCA cycle exists. However, the implication of the
citrate alternation is unclear although it was already noted in
Alzheimer’s and in MScl disease.37,44
Glutamine is an amino acid, which plays an important role in
brain metabolism. This metabolite is involved in energy meta-
bolism. It was shown that glutamine is a necessary nutrient for
cell proliferation, serving as a speciﬁc fuel for inﬂammatory cells
and enterocytes and, when present in appropriate concentra-
tions, enhancing cell function. During inﬂammatory states,
glutamine consumption may outstrip endogenous production
and a relative glutamine deﬁciency state may exist.45
A higher level of lactate was found in group “N10” in
comparison to group “N14”. Predominant lactate peaks have
already been reported in inﬂammatory CNS diseases. The
amount of CSF lactate depends largely on production from
CNS glycolysis. Increased lactate production by immune cells is
observable in the presence of inﬂammation. Although elevations
in CSF lactate may occur because of many diﬀerent processes, for
instance, hypoxia of inﬂamed tissues, reduced blood ﬂow from
cerebral edema, and granulocyte and bacterial metabolism.46 In
addition, elevated lactate levels have been identiﬁed in vitreous.
The reduced level of 3-hydroxyisovalerate was established for
group “N10” and group “P10” when compared with the healthy
group. This suggests that this metabolite is involved in peripheral
inﬂammation. However, this result deserves more attention since
a previous publication demonstrated an increase in 3-hydroxyi-
sovalerate level in some MScl patients.47
Conclusion
We investigated the eﬀect of neuroinﬂammation and periph-
eral inﬂammation on the metabolic state of CSF in the rat EAE
model, a mimic of the neuroinﬂammatory aspect of the early
stage of MScl. In the animal study untargeted and unbiased
biomarker discovery approach consisting of high-ﬁeld 1D 1H
NMR combined with multivariate data analysis was employed.
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CSF is demonstrated as a valuable bioﬂuid for the investiga-
tion of neurological disorders in the CNS. We found that 1H
NMR is a powerful technique capable of providing information
for the identiﬁcation and quantiﬁcation of a large number of
metabolites in CSF.
The use of two statistical techniques (PLS-DA and ANOVA-
PCA) contributes signiﬁcantly to the reliability of the results. The
two methods are corroborative, because the overall results
obtained by PLS-DA and ANOVA-PCA were found to be
coherent.
The CSF metabolic proﬁle for neuroinﬂammation is distinct
from that of healthy and peripheral inﬂammation and character-
ized by changes in concentrations of metabolites such as creatine,
arginine, and lysine. Peripheral inﬂammation was only seen at
Day 10 and absent at Day 14. A further interesting observation
was that the correlation network map is much more complex for
the healthy group than for the groups aﬀected by peripheral
inﬂammation or neuroinﬂammation. Disappearance of correla-
tion between metabolites in peripherally inﬂamed and neuroin-
ﬂamed animals might be related to change of penetrability of the
bloodbrain barrier (BBB). Under standard physiological cir-
cumstances, BBB controls the homeostasis of the interstitial
cerebral ﬂuid.48 It is known that during EAE changes in the BBB
function occur. It causes disruption in the BBB and eﬀects the
saturable transport system of substances involved in disease
process.49 Injection of CFA can itself lead to increased BBB
permeability to small molecules and even certain serum proteins.50
These disturbances might then cause changes in metabolites
ﬂux across BBB and relations between them. For instance, the
correlation might become more nonlinear or weaker and there-
fore be absent in the disease stage under a selected threshold. In
addition, in EAE there is a strong increase in inﬁltration of the
BBB by monocytes and activated lymphocytes that is bound to
change the metabolite proﬁle of the ﬂuids. Not only a disrupted
BBB leads to “leakage” but activated immune cells crossing the
BBB and entering the interstitial ﬂuid and the CSF produce
metabolites that change the overall proﬁle of the ﬂuids they
are in.
Interestingly, some markers of neuroinﬂammation have been
connected to demyelination and neuronal damage. In EAE
model induced with MBP demyelination is missing or limited
to the ventral root exit and dorsal root entry zone of the spinal
cord. In the case of Lewis rats primary demyelination is restricted
to occasional perivenous myelin sheaths. In general, demyelina-
tion is more distinct when addition of other CNS antigens to the
MBP results in pronounced demyelination. In addition, some
demyelination was observed in guinea pig EAE model incorpo-
rated with MBP inoculums utilized for sensitization.51 However,
the presence of demyelination in the EAE model induced with
MBP is a matter of debate. Therefore, we believe that it needs
additional investigations. In the current study, the presence of
demyelination could be investigated by, for instance, repeating
the EAEmodel and then performing histology studies or electron
microscopy of spinal cord. Another possibility would be to use
Magnetic magnetic resonance imaging to study the pathology of
rats’ brain and spinal cord. These steps could demonstrate the
presence or absence of demyelination.
By using an independent set of animals, that is, coming from
another EAE experiment, we demonstrated that this model and
ipso facto the disease speciﬁc markers have ability to predict
neuroinﬂammation in its early stage with high accuracy. Thus,
these animal-model-based markers may be used to diagnose the
early stage of neuroinﬂammation. Further developments will
include the investigation and translation of our results to
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